Becton Dickinson and Co
NYSE:BDX
Intrinsic Value
Becton, Dickinson & Co. is a medical technology company. [ Read More ]
The intrinsic value of one BDX stock under the Base Case scenario is 280.57 USD. Compared to the current market price of 234.12 USD, Becton Dickinson and Co is Undervalued by 17%.
Valuation Backtest
Becton Dickinson and Co
Run backtest to discover the historical profit from buying and selling BDX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Becton Dickinson and Co
Current Assets | 8.2B |
Cash & Short-Term Investments | 1.2B |
Receivables | 2.3B |
Other Current Assets | 4.7B |
Non-Current Assets | 44.1B |
PP&E | 6.6B |
Intangibles | 35.2B |
Other Non-Current Assets | 2.3B |
Current Liabilities | 7.5B |
Accounts Payable | 5.5B |
Other Current Liabilities | 2B |
Non-Current Liabilities | 19.4B |
Long-Term Debt | 14.1B |
Other Non-Current Liabilities | 5.3B |
Earnings Waterfall
Becton Dickinson and Co
Revenue
|
19.5B
USD
|
Cost of Revenue
|
-11.4B
USD
|
Gross Profit
|
8.1B
USD
|
Operating Expenses
|
-6B
USD
|
Operating Income
|
2.1B
USD
|
Other Expenses
|
-832m
USD
|
Net Income
|
1.2B
USD
|
Free Cash Flow Analysis
Becton Dickinson and Co
What is Free Cash Flow?
BDX Profitability Score
Profitability Due Diligence
Becton Dickinson and Co's profitability score is 52/100. The higher the profitability score, the more profitable the company is.
Score
Becton Dickinson and Co's profitability score is 52/100. The higher the profitability score, the more profitable the company is.
BDX Solvency Score
Solvency Due Diligence
Becton Dickinson and Co's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Score
Becton Dickinson and Co's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BDX Price Targets Summary
Becton Dickinson and Co
According to Wall Street analysts, the average 1-year price target for BDX is 284.11 USD with a low forecast of 242.4 USD and a high forecast of 330.75 USD.
Ownership
BDX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
BDX Price
Becton Dickinson and Co
Average Annual Return | 5.75% |
Standard Deviation of Annual Returns | 12.11% |
Max Drawdown | -30% |
Market Capitalization | 67.9B USD |
Shares Outstanding | 288 902 016 |
Percentage of Shares Shorted | 1.01% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Becton, Dickinson & Co. is a medical technology company. The company is headquartered in Franklin Lakes, New Jersey and currently employs 75,000 full-time employees. The firm operates through three business segments: BD Medical, BD Life Sciences and BD Interventional. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. BD Medical consists of various business units, including medication delivery solutions, medication management solutions, diabetes care and pharmaceutical systems. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. The BD Interventional segment provides vascular, urology, oncology and surgical specialty products.
Contact
IPO
Employees
Officers
The intrinsic value of one BDX stock under the Base Case scenario is 280.57 USD.
Compared to the current market price of 234.12 USD, Becton Dickinson and Co is Undervalued by 17%.